Resources

Online Inquiry

* Your Name

Phone Number

* E-mail Address

* Services Interested

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Rare Kidney Disease Drug Discovery & Development Solutions

As your essential partner in advancing rare kidney disease therapies, Protheragen is a global leader in integrated R&D solutions. We deliver an unrivaled suite of services, from target discovery and preclinical development through to IITs. Leveraging deep scientific expertise, cutting-edge technologies, and tailored end-to-end support, we precisely accelerate your therapeutic programs for maximum potential.

DOWNLOAD THE PDF

Customized Solutions

Therapeutic Development

Protheragen specializes in pioneering transformative therapies for rare kidney diseases, leveraging cutting-edge technologies to accelerate the discovery and preclinical validation of diverse new therapeutics.

Disease Model Development

Protheragen develops diverse and highly predictive disease models to accurately mimic rare kidney pathologies and support robust R&D.

Animal Models Development

Animal Models for Rare Kidney Disease Research

Diseases	Animal Models
Alport Syndrome	Genetically Engineered Models (e.g., Col4a3/a4/a5 knockout/mutant mice)
Polycystic Kidney Disease (PKD)	Genetically Engineered Models (e.g., Pkd1/Pkd2 mutant mice); Induced Cyst Models
Fabry Disease	Genetically Engineered Models (e.g., Gla knockout mice)
IgA Nephropathy	Induced Disease Models (various IgAN mouse models); Humanized Animal Models
Focal Segmental Glomerulosclerosis (FSGS)	Induced Disease Models (e.g., Adriamycin-induced); Genetically Engineered Models
Atypical Hemolytic Uremic Syndrome (aHUS)	Genetically Engineered Models (e.g., complement pathway gene modifications)
Lupus Nephritis	Induced Disease Models (e.g., specific autoimmune mouse strains, pristane-induced models)
Renal Cell Carcinoma (RCC)	Syngeneic Models; Xenograft Models; Genetically Engineered Models (e.g., VHL knockout)
Cystinosis	Genetically Engineered Models (e.g., Ctns knockout mice)
Nephrotic Syndrome (Congenital/Steroid-Resistant)	Genetically Engineered Models (e.g., Nphs1/Nphs2 mutations); Induced Podocytopathy Models

Case Study —— Alport Syndrome Models

A robust experimental design was employed in our study to investigate potential therapeutic interventions for Alport Syndrome (AS). The well-established COL4A3^−/− mouse model, which faithfully recapitulates the key pathological features of human AS, was utilized. All treatments (IgG or Antibody X) were commenced at Week 6 of age, a time point when the disease is already established in the COL4A3^−/− model, mimicking a more clinically relevant intervention window for patients with existing disease. Treatment was continued until Week 8.5, allowing the short-to-medium term impact on disease progression to be assessed.

Fig1. Antibody X improves body weight, reduces kidney fibrosis, and attenuates proteinuria in Alport Syndrome Mice. a) Body weight. b) quantification (from 100× field images) of Masson’s trichrome staining. c) urinary albumin-creatinine ratios(*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 6 )

Partner with Protheragen, your essential ally in navigating the complexities of rare kidney disease drug discovery and development. From groundbreaking target identification to robust preclinical validation and beyond, our integrated R&D solutions are meticulously designed to accelerate your therapeutic programs.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.